Coherus Oncology Inc (CHRS)

EBITDA

-$148.46M

TTM · Period ending: · USD

CHRS logo

CHRS EBITDA

Latest reported-$148.46M
CHRS TTM EBITDA (-$49.09M → -$148.46M)
High-resolution chart · PNG

CHRS ebitda history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Coherus Oncology Inc EBITDA — Trailing twelve months (TTM) (USD)
Period endingEBITDA (USD)
-148,458,000
-159,865,000
-170,199,000
-171,314,000
-133,928,000
-98,759,000
-117,968,000
-141,622,000
-166,636,000
-192,282,000
-193,939,000
-174,403,000
-223,664,000
-234,301,000
-255,581,000
-245,653,000
-199,403,000
-179,996,000
-260,098,000
-204,320,000
-137,990,000
-48,233,000
159,760,000
189,298,000
208,031,000
169,717,000
113,077,000
6,719,000
-102,080,000
-170,613,000
-196,488,000
-182,682,000
-182,926,000
-194,740,000
-225,349,000
-252,384,000
-109,522,000
-120,078,000
-112,132,000
-90,578,000
-248,411,000
-244,309,000
-221,281,000
-195,048,000
-131,953,000
-97,100,000
-78,806,000
-64,997,000
-76,656,000
-62,060,000
-49,090,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.